[go: up one dir, main page]

AR034448A1 - Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones - Google Patents

Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones

Info

Publication number
AR034448A1
AR034448A1 ARP020102172A ARP020102172A AR034448A1 AR 034448 A1 AR034448 A1 AR 034448A1 AR P020102172 A ARP020102172 A AR P020102172A AR P020102172 A ARP020102172 A AR P020102172A AR 034448 A1 AR034448 A1 AR 034448A1
Authority
AR
Argentina
Prior art keywords
alkylaminoethyl
hydrogen
alkyl
hydroxyl
halogen
Prior art date
Application number
ARP020102172A
Other languages
English (en)
Inventor
Christopher John Hobbs
Wen-Rong Jiang
Joseph Armstrong Martin
John Herbert Merrett
Isabel Najera
Nobuo Shimma
Takuo Tsukuda
Rene Robert Devos
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR034448A1 publication Critical patent/AR034448A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso de derivados de nucleósidos de fórmula (1) en donde: R es hidrógeno o -[P(O)(OH)-O]nH y n es 1, 2 o 3; R1 es alquilo, alquenilo, alquinilo, haloalquilo, alquilcarbonilo, alcoxicarbonilo, hidroxialquilo, alcoxialquilo, alcoxilo, ciano, azido, hidroxiiminometilo, alcoxiiminometilo, halógeno, alquilcarbonilamino, alquilaminocarbonilo, azidoalquilo, aminometilo, alquilaminometilo, dialquilaminometilo o heterociclilo; R2 es hidrógeno, hidroxilo, amino, alquilo, hidroxialquilo, alcoxilo, halógeno, ciano, o azido; R3 y R4 son hidrógeno, hidroxilo, alcoxilo, halógeno o hidroxialquilo, con la condición de que por lo menos uno de R3 y R4 sea hidrógeno; o R3 y R4 juntos, representan =CH2 o =N-OH, o R3 y R4 representan flúor los dos; X es O, S o CH2; B significa un radical 9-purinilo B1 de fórmula (2), en donde: R5 es hidrógeno, hidroxilo, alquilo, alcoxilo, alquiltio, NHR8, halógeno o SH; R6 es hidroxilo, NHR8, NHOR9, NHNR8, -NHC(O)OR9' o SH; R7 es hidrógeno, hidroxilo, alquilo, alcoxilo, alquiltio, NHR8, halógeno, SH o ciano; R8 es hidrógeno, alquilo, hidroxialquilo, arilcarbonilo o alquilcarbonilo; R9 es hidrógeno o alquilo; R9' es alquilo; y B significa un radical 1-pirimidilo B2, de fórmula (3), en donde: Z es O o S; R10 es hidroxilo, NHR8, NHOR9, NHNR8, -NHC(O)OR9' o SH; R11 es hidrógeno, alquilo, hidroxilo, hidroxialquilo, alcoxialquilo, haloalquilo o halógeno; R8, R9 y R9' son como se ha definido más arriba; y de las sales farmacéuticamente aceptables de los mismos; para el tratamiento de enfermedades inducidas por el virus de la hepatitis C (HCV) y para la preparación de un medicamento para dicho tratamiento. El derivado de nucleósido definido arriba o una sal farmacéuticamente aceptable del mismo para el tratamiento de enfermedades inducidas por el virus de la hepatitis C (HCV); composición farmacéutica que comprende del derivado; y uso de la composición farmacéutica.
ARP020102172A 2001-06-12 2002-06-10 Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones AR034448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0114286.8A GB0114286D0 (en) 2001-06-12 2001-06-12 Nucleoside Derivatives

Publications (1)

Publication Number Publication Date
AR034448A1 true AR034448A1 (es) 2004-02-25

Family

ID=9916416

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102172A AR034448A1 (es) 2001-06-12 2002-06-10 Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones

Country Status (39)

Country Link
US (6) US6784166B2 (es)
EP (1) EP1404347B1 (es)
JP (1) JP4265969B2 (es)
KR (1) KR100587747B1 (es)
CN (1) CN100528173C (es)
AR (1) AR034448A1 (es)
AT (1) ATE315938T1 (es)
AU (1) AU2002317782B2 (es)
BG (1) BG66355B1 (es)
BR (1) BR0210350A (es)
CA (1) CA2449572C (es)
CZ (1) CZ306042B6 (es)
DE (1) DE60208794T2 (es)
DK (1) DK1404347T3 (es)
EC (1) ECSP034897A (es)
ES (1) ES2256494T3 (es)
GB (1) GB0114286D0 (es)
GT (1) GT200200117A (es)
HR (1) HRPK20031003B3 (es)
HU (1) HU230321B1 (es)
IL (2) IL159023A0 (es)
JO (1) JO2399B1 (es)
MA (1) MA27040A1 (es)
ME (1) MEP26208A (es)
MX (1) MXPA03011192A (es)
NO (1) NO334255B1 (es)
NZ (1) NZ529695A (es)
PA (1) PA8547701A1 (es)
PE (1) PE20030256A1 (es)
PL (1) PL204741B1 (es)
PT (1) PT1404347E (es)
RS (1) RS51871B (es)
RU (1) RU2322989C2 (es)
SI (1) SI1404347T1 (es)
SK (1) SK287875B6 (es)
TW (1) TWI313176B (es)
UY (1) UY27333A1 (es)
WO (1) WO2002100415A2 (es)
ZA (1) ZA200309169B (es)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414520T1 (de) 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
WO2003026675A1 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
WO2003068796A1 (en) * 2002-02-15 2003-08-21 Yamasa Corporation 4’-c-cyano-2’-deoxypurine nucleosides
EA008775B1 (ru) 2002-04-26 2007-08-31 Джилид Сайэнс, Инк. Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
MXPA05001298A (es) 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
TWI294882B (en) * 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
BR0316868A (pt) * 2002-12-23 2005-10-25 Idenix Cayman Ltd Processo para a produção de pró-medicamentos de nucleosìdeo-3'
AU2003300544A1 (en) * 2003-01-09 2004-08-10 F. Hoffmann-La Roche Ag -modified nucleoside derivatives for treating flaviviridae infections
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
US7294877B2 (en) * 2003-03-28 2007-11-13 Nantero, Inc. Nanotube-on-gate FET structures and applications
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7417055B2 (en) 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
KR20060026426A (ko) * 2003-06-19 2006-03-23 에프. 호프만-라 로슈 아게 4'-아지도 뉴클레오사이드 유도체의 제조 방법
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2543294A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
AU2004309418B2 (en) * 2003-12-22 2012-01-19 Gilead Sciences, Inc. 4'-substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
KR20120091276A (ko) 2004-02-20 2012-08-17 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
AU2005267421B2 (en) 2004-06-24 2010-06-03 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
JP2008508291A (ja) 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体
DE602005015466D1 (de) 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
RU2008107972A (ru) 2005-08-01 2009-09-10 Мерк энд Ко., Инк. (US) Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
BRPI0615157A2 (pt) * 2005-08-12 2016-09-13 Merck & Co Inc composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AU2007263726A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
NZ575889A (en) 2006-10-10 2011-09-30 Medivir Ab Hcv nucleoside inhibitor
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
EP2083844B1 (en) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2086982B1 (en) * 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
DE602007008616D1 (de) * 2006-12-11 2010-09-30 Hoffmann La Roche Verfahren zur herstellung von 4'-azidocytidinderivaten
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
HRP20110115T1 (hr) * 2007-02-19 2011-03-31 Glaxosmithkline Llc Derivati purina kao imunomodulatori
PL2144604T3 (pl) 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101784557A (zh) * 2007-05-14 2010-07-21 Rfs制药公司 用于治疗病毒感染的叠氮基嘌呤核苷
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AR069740A1 (es) * 2007-11-29 2010-02-17 Metabasis Therapeutics Inc Compuestos nucleosidos antivirales
CA2720850A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201012814A (en) * 2008-07-01 2010-04-01 Centocor Ortho Biotech Products L P Cyclopropyl polymerase inhibitors
EP2307434B1 (en) * 2008-07-02 2014-02-12 IDENIX Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2307435B1 (en) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
US20100029655A1 (en) * 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
PL2310095T3 (pl) 2008-07-22 2013-03-29 Msd Italia Srl Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
JP2011530562A (ja) * 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
WO2010018130A1 (en) * 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
CN104530048B (zh) * 2008-08-11 2016-09-14 葛兰素史密丝克莱恩有限责任公司 腺嘌呤衍生物
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
BRPI1005401A2 (pt) 2009-02-06 2019-04-02 Rfs Pharma, Llc pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
WO2011092158A1 (en) * 2010-01-28 2011-08-04 F. Hoffmann-La Roche Ag 4 ' - azido - nucleosides as anti - hcv compunds
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
JP2014511875A (ja) 2011-04-13 2014-05-19 メルク・シャープ・アンド・ドーム・コーポレーション ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP2734186B1 (en) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Composition
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US20130244966A1 (en) * 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
LT2794628T (lt) * 2011-12-20 2017-07-10 Riboscience Llc 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
DK2883866T3 (da) * 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
BR112015007698A2 (pt) 2012-10-08 2017-08-22 Idenix Pharmaceuticals Inc Centre National De La Recherche Scientifique E Univ Montpellier 2 Science Composto, composição farmacêutica, e, uso de um composto
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
NZ707319A (en) 2012-11-20 2019-09-27 Glaxosmithkline Llc 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
RU2534613C2 (ru) * 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
RU2015148006A (ru) 2013-04-12 2017-05-18 Ачиллион Фармасютикалз, Инк. Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
MA38678A1 (fr) * 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
GEP201706793B (en) * 2013-06-26 2017-12-11 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) * 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
JP6581100B2 (ja) * 2014-02-06 2019-09-25 リボサイエンス・エルエルシー インフルエンザｒｎａ複製の阻害剤としての４’−ジフルオロメチル置換ヌクレオシド誘導体
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3197457B1 (en) * 2014-09-26 2022-11-09 Riboscience LLC 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
US20160237106A1 (en) * 2015-01-14 2016-08-18 Riboscience Llc 4'-azido substituted nucleoside derivatives as inhibitors of ebola virus rna replication
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
KR101747314B1 (ko) 2015-07-01 2017-06-15 건국대학교 산학협력단 이중형광마커 형질전환 마우스를 이용한 만능줄기세포 구별방법
JP6767011B2 (ja) * 2015-09-18 2020-10-14 ヤマサ醤油株式会社 抗ｄｎａウィルス活性などの生理活性を有するヌクレオシド誘導体
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
KR102073566B1 (ko) 2018-07-19 2020-02-05 한밭대학교 산학협력단 C형 간염 치료 및 예방용 조성물
CN109385459A (zh) * 2018-10-18 2019-02-26 大连理工大学 一种细胞分裂素通过抑制dna聚合酶活性抑制细胞增殖的方法
KR102686384B1 (ko) * 2019-04-05 2024-07-17 가부시기가이샤 닛뽕쇼꾸바이 가교형 인공 뉴클레오시드의 제조
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN113735927B (zh) * 2021-10-18 2024-06-28 厦门蔚扬药业有限公司 一种核苷酸类似物及其制备方法和用途
WO2023073239A1 (en) 2021-11-01 2023-05-04 Immunic Ag Medical use of n4-hydroxy citicoline compounds
PE20250684A1 (es) 2022-03-15 2025-03-04 Rome Therapeutics Inc Compuestos y metodos para el tratamiento de enfermedades
WO2024015916A2 (en) * 2022-07-13 2024-01-18 Thomas Jefferson University 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910885A (en) * 1974-03-12 1975-10-07 Syntex Inc 4-Alkoxy nucleosides and intermediates therefore
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds
US5155112A (en) * 1988-06-03 1992-10-13 Glaxo Group Limited Cyclopentane derivatives
US5449664A (en) * 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
KR900007863A (ko) * 1988-11-21 1990-06-02 원본미기재 향비루스제
JPH0720741B2 (ja) 1988-11-28 1995-03-08 株式会社東京機械製作所 ダンプニングローラー、ダンプニングローラーの製造方法および印刷機の湿し水供給装置
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
AU7623991A (en) * 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
KR100263943B1 (ko) * 1991-02-08 2000-08-16 마아크 짐머 조혈 개선을 위한 옥시푸린 뉴클레오시드 및 그의 동종체 및 그의 아실 유도체
JP2924207B2 (ja) * 1991-02-14 1999-07-26 松下電器産業株式会社 ディスク再生装置
JPH05230058A (ja) * 1992-02-24 1993-09-07 Yamasa Shoyu Co Ltd ４’−炭素置換ピリミジンヌクレオシド及びその製造法
DE4207363A1 (de) 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
JP2545174B2 (ja) * 1992-04-20 1996-10-16 羽田コンクリート工業株式会社 表面板の先付方法
JPH0660688A (ja) 1992-05-18 1994-03-04 Nec Corp サンプル・ホールド回路
WO1994001117A1 (en) * 1992-07-02 1994-01-20 The Wellcome Foundation Limited Therapeutic nucleosides
JPH0680688A (ja) * 1992-09-03 1994-03-22 Asahi Breweries Ltd ４’−メチルヌクレオシド誘導体
CA2156394A1 (en) * 1993-02-24 1994-09-01 Jui H. Wang Compositions and methods of application of reactive antiviral polymers
CN1041631C (zh) * 1993-06-21 1999-01-13 默里尔药物公司 用作炎症前细胞因子选择性抑制剂的新的碳环核苷药物
JPH07126282A (ja) 1993-11-01 1995-05-16 Nippon Kayaku Co Ltd 新規なチオヌクレオシド誘導体
US5681940A (en) * 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
EP0799834A1 (en) * 1996-04-04 1997-10-08 Novartis AG Modified nucleotides
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
DE69729887T2 (de) * 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
EA200700564A1 (ru) * 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
JP4211901B2 (ja) * 1998-06-08 2009-01-21 ヤマサ醤油株式会社 ４’−メチルヌクレオシド化合物
ES2207504T3 (es) * 1999-05-12 2004-06-01 Yamasa Corporation Nucleosidos 4'-c-etinilpurina.
EP1225899A2 (en) * 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
BR0016415A (pt) 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
MXPA02008078A (es) * 2000-02-18 2002-11-29 Julio Javier Cristiani Metodo para el tratamiento o prevencion de infecciones por flavivirus utilizando analogos de nucleosidos.
ATE414520T1 (de) * 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) * 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003026675A1 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US20070032448A1 (en) * 2002-01-17 2007-02-08 Zhi Hong Sugar modified nucleosides as viral replication inhibitors

Also Published As

Publication number Publication date
EP1404347B1 (en) 2006-01-18
AU2002317782B2 (en) 2007-11-22
BG66355B1 (bg) 2013-09-30
SK287875B6 (sk) 2012-02-03
RS51871B (sr) 2012-02-29
DE60208794D1 (de) 2006-04-06
WO2002100415A2 (en) 2002-12-19
DK1404347T3 (da) 2006-05-29
US20030236216A1 (en) 2003-12-25
CZ306042B6 (cs) 2016-07-13
NO20035524D0 (no) 2003-12-11
ZA200309169B (en) 2005-05-25
TWI313176B (en) 2009-08-11
GT200200117A (es) 2003-06-19
HK1065707A1 (zh) 2005-03-04
US20100003213A1 (en) 2010-01-07
YU98103A (sh) 2006-05-25
HUP0401291A3 (en) 2007-05-29
US6784166B2 (en) 2004-08-31
US7915232B2 (en) 2011-03-29
IL159023A0 (en) 2004-05-12
ME00195B (me) 2010-10-10
KR100587747B1 (ko) 2006-06-09
PL366726A1 (en) 2005-02-07
US20040266722A1 (en) 2004-12-30
ATE315938T1 (de) 2006-02-15
CA2449572A1 (en) 2002-12-19
CN100528173C (zh) 2009-08-19
BG108439A (en) 2005-03-31
HRPK20031003B3 (en) 2006-02-28
US20100004192A1 (en) 2010-01-07
DE60208794T2 (de) 2006-08-31
MXPA03011192A (es) 2004-02-26
SI1404347T1 (sl) 2006-04-30
PE20030256A1 (es) 2003-03-19
HU230321B1 (hu) 2016-01-28
JP4265969B2 (ja) 2009-05-20
NZ529695A (en) 2006-08-31
US8648054B2 (en) 2014-02-11
CN1516590A (zh) 2004-07-28
PA8547701A1 (es) 2003-07-28
MA27040A1 (fr) 2004-12-20
JO2399B1 (en) 2007-06-17
NO334255B1 (no) 2014-01-20
US20130237491A1 (en) 2013-09-12
UY27333A1 (es) 2003-03-31
HRP20031003A2 (en) 2004-06-30
CZ20033543A3 (cs) 2004-09-15
US8071567B2 (en) 2011-12-06
PL204741B1 (pl) 2010-02-26
ES2256494T3 (es) 2006-07-16
WO2002100415A3 (en) 2003-08-07
US20120034184A1 (en) 2012-02-09
EP1404347A2 (en) 2004-04-07
RU2003137561A (ru) 2005-06-10
ECSP034897A (es) 2004-01-28
KR20040018267A (ko) 2004-03-02
MEP26208A (en) 2010-10-10
CA2449572C (en) 2009-10-13
JP2004536817A (ja) 2004-12-09
HUP0401291A2 (hu) 2004-10-28
PT1404347E (pt) 2006-05-31
IL159023A (en) 2010-04-29
GB0114286D0 (en) 2001-08-01
BR0210350A (pt) 2004-07-20
US7608601B2 (en) 2009-10-27
RU2322989C2 (ru) 2008-04-27
SK16222003A3 (sk) 2004-12-01

Similar Documents

Publication Publication Date Title
AR034448A1 (es) Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones
PA8588501A1 (es) Derivados antivirales de nucleósidos
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
DK2097434T3 (da) Nukleosidarylphosphoramidater og deres anvendelse som antivirale midler til behandlingen af hepatitis C virus
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
PE20140522A1 (es) Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
NO20073357L (no) 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
TNSN08022A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
BRPI0407699A (pt) Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
AR035285A1 (es) Formulaciones en combinacion de derivados de1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion.

Legal Events

Date Code Title Description
FC Refusal